| Name | Title | Contact Details |
|---|
Receptor Life Sciences, Inc. develops inhaled therapeutic products for conditions including chronic pain, neurologic diseases, and inflammatory disorders.
Imago BioSciences is translating true scientific insights into transformative treatments allowing patients to live longer, disease-free lives.
Volcano Corporation designs, develops, manufactures and commercializes a suite of intravascular ultrasound (IVUS) and functional measurement (FM) products that seeks to enhance the diagnosis and treatment of vascular and structural heart disease. The
We founded Cedilla at a time of fundamental and rapidly growing insight into the mechanisms underlying protein stability. Small molecules that degrade or stablize target proteins are precedented, but have been discovered serendipitously. Cedilla is taking an integrated approach to discover new drugs with this mode of action. Our present focus is to develop novel medicines in oncology, but this approach will also be applicable to other fields, including central nervous system disorders and genetic diseases. Cedilla launched with $56.2 million in Series A funding from Third Rock Ventures.
BELLUS Health is a clinical stage biotechnology company developing novel therapeutics for the treatment of chronic cough and other chronic disorders triggered by hypersensitization.